Skip to main content
Erschienen in: Abdominal Radiology 4/2020

11.01.2020 | Hepatobiliary

The added value of dual-time-point 18F-FDG PET/CT imaging in the diagnosis of colorectal cancer liver metastases

verfasst von: Wujian Mao, Jun Zhou, Lin Qiu, Hongyan Yin, Hui Tan, Hongcheng Shi

Erschienen in: Abdominal Radiology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the added value of dual-time-point 18F-FDG PET/CT imaging in the diagnosis of colorectal cancer liver metastases (CRLM).

Methods

One hundred and eight patients with CRLM preoperatively underwent a dual-time-point 18F-FDG PET/CT scan. All hepatic lesions were diagnosed by histopathology. The diagnostic sensitivity of 18F-FDG PET/CT for CRLM was calculated on early scan and delayed scan, respectively. The McNemar test was used to test the differences of the sensitivity and the specificity between early scan and delayed scan.

Results

On a per-patient basis, no significant difference in sensitivity was found between early scan and delayed scan (92.93% vs. 96.97%, P = 0.125). The per-patient specificity of early and delayed scans was 77.78%. On a per-lesion basis, overall sensitivity of delayed scan was significantly higher than that of early scan (83.49% vs. 76.61%, P < 0.001). The per-lesion specificity of early and delayed scans was 69.23%. For the lesion size of CRLM ≤ 10 mm, delayed imaging had significantly higher sensitivity than early imaging (47.17% vs. 26.42%, P < 0.001). However, for CRLM > 10 mm, there was no significant difference in sensitivity between early and delayed scans (92.73% vs. 95.15%, P = 0.125). Of the detected 182 liver metastatic lesions on delayed scan, the SUVmax on delayed scan was significantly higher than that on early scan (12.13 ± 7.13 vs. 9.16 ± 4.74, P < 0.001). The SUVmean of the normal liver on delayed scan was significantly lower than that on early scan (1.91 ± 0.29 vs. 2.33 ± 0.31, P < 0.001). The tumor to normal background ratio on delayed scan was significantly higher than that on early scan (6.59 ± 4.43 vs. 4.02 ± 2.23, P < 0.001).

Conclusion

The dual-time-point 18F-FDG PET/CT imaging might detect more CRLM lesions compared with single-time-point imaging, especially for small (< 10 mm) lesions.
Literatur
1.
Zurück zum Zitat Torre LA, Bray F, Siegel RL, et al. (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87-108.CrossRef Torre LA, Bray F, Siegel RL, et al. (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87-108.CrossRef
2.
Zurück zum Zitat Abdalla EK, Adam R, Bilchik AJ, et al. (2006) Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 13(10):1271-1280.CrossRef Abdalla EK, Adam R, Bilchik AJ, et al. (2006) Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 13(10):1271-1280.CrossRef
3.
Zurück zum Zitat Kemeny NE, Melendez FD, Capanu M, et al. (2009) Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 27(21):3465-3471.CrossRef Kemeny NE, Melendez FD, Capanu M, et al. (2009) Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 27(21):3465-3471.CrossRef
4.
Zurück zum Zitat Kopetz S, Chang GJ, Overman MJ, et al. (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27(22):3677-3683.CrossRef Kopetz S, Chang GJ, Overman MJ, et al. (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27(22):3677-3683.CrossRef
5.
Zurück zum Zitat House MG, Ito H, Gonen M, et al. (2010) Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg 210(5):744-752, 752-755. House MG, Ito H, Gonen M, et al. (2010) Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg 210(5):744-752, 752-755.
6.
Zurück zum Zitat Nordlinger B, Sorbye H, Glimelius B, et al. (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14(12):1208-1215.CrossRef Nordlinger B, Sorbye H, Glimelius B, et al. (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14(12):1208-1215.CrossRef
7.
Zurück zum Zitat Nanji S, Cleary S, Ryan P, et al. (2013) Up-front hepatic resection for metastatic colorectal cancer results in favorable long-term survival. Ann Surg Oncol 20(1):295-304.CrossRef Nanji S, Cleary S, Ryan P, et al. (2013) Up-front hepatic resection for metastatic colorectal cancer results in favorable long-term survival. Ann Surg Oncol 20(1):295-304.CrossRef
8.
Zurück zum Zitat Ko Y, Kim J, Park JK, et al. (2017) Limited detection of small (</= 10 mm) colorectal liver metastasis at preoperative CT in patients undergoing liver resection. PLoS One 12(12):e189797. Ko Y, Kim J, Park JK, et al. (2017) Limited detection of small (</= 10 mm) colorectal liver metastasis at preoperative CT in patients undergoing liver resection. PLoS One 12(12):e189797.
9.
Zurück zum Zitat Oh J, Oh SN, Choi JI, et al. (2016) Does the Gadoxetic Acid-Enhanced Liver MRI Impact on the Treatment of Patients with Colorectal Cancer? Comparison Study with18F-FDG PET/CT. Biomed Res Int 2016: 8412071.PubMedPubMedCentral Oh J, Oh SN, Choi JI, et al. (2016) Does the Gadoxetic Acid-Enhanced Liver MRI Impact on the Treatment of Patients with Colorectal Cancer? Comparison Study with18F-FDG PET/CT. Biomed Res Int 2016: 8412071.PubMedPubMedCentral
10.
Zurück zum Zitat Georgakopoulos A, Pianou N, Kelekis N, et al. (2013) Impact of 18F-FDG PET/CT on therapeutic decisions in patients with colorectal cancer and liver metastases. Clin Imaging 37(3):536-541.CrossRef Georgakopoulos A, Pianou N, Kelekis N, et al. (2013) Impact of 18F-FDG PET/CT on therapeutic decisions in patients with colorectal cancer and liver metastases. Clin Imaging 37(3):536-541.CrossRef
11.
Zurück zum Zitat Koyama K, Okamura T, Kawabe J, et al. (2002) The usefulness of 18F-FDG PET images obtained 2 hours after intravenous injection in liver tumor. Ann Nucl Med 16(3):169-176.CrossRef Koyama K, Okamura T, Kawabe J, et al. (2002) The usefulness of 18F-FDG PET images obtained 2 hours after intravenous injection in liver tumor. Ann Nucl Med 16(3):169-176.CrossRef
12.
Zurück zum Zitat Lin WY, Tsai SC, Hung GU. (2005) Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma. Nucl Med Commun 26(4):315-321.CrossRef Lin WY, Tsai SC, Hung GU. (2005) Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma. Nucl Med Commun 26(4):315-321.CrossRef
13.
Zurück zum Zitat Dirisamer A, Halpern BS, Schima W, et al. (2008) Dual-time-point FDG-PET/CT for the detection of hepatic metastases. Mol Imaging Biol 10(6):335-340.CrossRef Dirisamer A, Halpern BS, Schima W, et al. (2008) Dual-time-point FDG-PET/CT for the detection of hepatic metastases. Mol Imaging Biol 10(6):335-340.CrossRef
14.
Zurück zum Zitat Wu B, Zhao Y, Zhang Y, et al. (2017) Does dual-time-point 18F-FDG PET/CT scan add in the diagnosis of hepatocellular carcinoma? Hell J Nucl Med 20(1):79-82.PubMed Wu B, Zhao Y, Zhang Y, et al. (2017) Does dual-time-point 18F-FDG PET/CT scan add in the diagnosis of hepatocellular carcinoma? Hell J Nucl Med 20(1):79-82.PubMed
15.
Zurück zum Zitat Annovazzi A, Rea S, Vici P, et al. (2018) Dual-time 18F-FDG PET/CT for the detection of liver metastases in breast cancer. Nucl Med Commun 39(12):1183-1189.CrossRef Annovazzi A, Rea S, Vici P, et al. (2018) Dual-time 18F-FDG PET/CT for the detection of liver metastases in breast cancer. Nucl Med Commun 39(12):1183-1189.CrossRef
16.
Zurück zum Zitat Lee JW, Kim SK, Lee SM, et al. (2011) Detection of hepatic metastases using dual-time-point FDG PET/CT scans in patients with colorectal cancer. Mol Imaging Biol 13(3):565-572.CrossRef Lee JW, Kim SK, Lee SM, et al. (2011) Detection of hepatic metastases using dual-time-point FDG PET/CT scans in patients with colorectal cancer. Mol Imaging Biol 13(3):565-572.CrossRef
17.
Zurück zum Zitat Schulz A, Viktil E, Godt JC, et al. (2016) Diagnostic performance of CT, MRI and PET/CT in patients with suspected colorectal liver metastases: the superiority of MRI. Acta Radiol 57(9):1040-1048.CrossRef Schulz A, Viktil E, Godt JC, et al. (2016) Diagnostic performance of CT, MRI and PET/CT in patients with suspected colorectal liver metastases: the superiority of MRI. Acta Radiol 57(9):1040-1048.CrossRef
18.
Zurück zum Zitat Rappeport ED, Loft A, Berthelsen AK, et al. (2007) Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Acta Radiol 48(4):369-378. Rappeport ED, Loft A, Berthelsen AK, et al. (2007) Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Acta Radiol 48(4):369-378.
19.
Zurück zum Zitat Colagrande S, Castellani A, Nardi C, et al. (2016) The role of diffusion-weighted imaging in the detection of hepatic metastases from colorectal cancer: A comparison with unenhanced and Gd-EOB-DTPA enhanced MRI. Eur J Radiol 85(5):1027-1034.CrossRef Colagrande S, Castellani A, Nardi C, et al. (2016) The role of diffusion-weighted imaging in the detection of hepatic metastases from colorectal cancer: A comparison with unenhanced and Gd-EOB-DTPA enhanced MRI. Eur J Radiol 85(5):1027-1034.CrossRef
20.
Zurück zum Zitat Vreugdenburg TD, Ma N, Duncan JK, et al. (2016) Comparative diagnostic accuracy of hepatocyte-specific gadoxetic acid (Gd-EOB-DTPA) enhanced MR imaging and contrast enhanced CT for the detection of liver metastases: a systematic review and meta-analysis. Int J Colorectal Dis 31(11):1739-1749.CrossRef Vreugdenburg TD, Ma N, Duncan JK, et al. (2016) Comparative diagnostic accuracy of hepatocyte-specific gadoxetic acid (Gd-EOB-DTPA) enhanced MR imaging and contrast enhanced CT for the detection of liver metastases: a systematic review and meta-analysis. Int J Colorectal Dis 31(11):1739-1749.CrossRef
21.
Zurück zum Zitat Lee DH, Lee JM, Hur BY, et al. (2016) Colorectal Cancer Liver Metastases: Diagnostic Performance and Prognostic Value of PET/MR Imaging. Radiology 280(3):782-792.CrossRef Lee DH, Lee JM, Hur BY, et al. (2016) Colorectal Cancer Liver Metastases: Diagnostic Performance and Prognostic Value of PET/MR Imaging. Radiology 280(3):782-792.CrossRef
22.
Zurück zum Zitat Cheng G, Alavi A, Lim E, et al. (2013) Dynamic changes of FDG uptake and clearance in normal tissues. Mol Imaging Biol 15(3):345-352.CrossRef Cheng G, Alavi A, Lim E, et al. (2013) Dynamic changes of FDG uptake and clearance in normal tissues. Mol Imaging Biol 15(3):345-352.CrossRef
23.
Zurück zum Zitat Chin BB, Green ED, Turkington TG, et al. (2009) Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3 h. Mol Imaging Biol 11(2):118-122.CrossRef Chin BB, Green ED, Turkington TG, et al. (2009) Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3 h. Mol Imaging Biol 11(2):118-122.CrossRef
24.
Zurück zum Zitat Hamberg LM, Hunter GJ, Alpert NM, et al. (1994) The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 35(8):1308-1312.PubMed Hamberg LM, Hunter GJ, Alpert NM, et al. (1994) The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 35(8):1308-1312.PubMed
25.
Zurück zum Zitat Seo S, Hatano E, Higashi T, et al. (2009) P-glycoprotein expression affects 18F-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro. Int J Oncol 34(5):1303-1312.PubMed Seo S, Hatano E, Higashi T, et al. (2009) P-glycoprotein expression affects 18F-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro. Int J Oncol 34(5):1303-1312.PubMed
26.
Zurück zum Zitat Torizuka T, Tamaki N, Inokuma T, et al. (1995) In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36(10):1811-1817.PubMed Torizuka T, Tamaki N, Inokuma T, et al. (1995) In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36(10):1811-1817.PubMed
27.
Zurück zum Zitat Cheng G, Torigian DA, Zhuang H, et al. (2013) When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET? Eur J Nucl Med Mol Imaging 40(5):779-787.CrossRef Cheng G, Torigian DA, Zhuang H, et al. (2013) When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET? Eur J Nucl Med Mol Imaging 40(5):779-787.CrossRef
Metadaten
Titel
The added value of dual-time-point 18F-FDG PET/CT imaging in the diagnosis of colorectal cancer liver metastases
verfasst von
Wujian Mao
Jun Zhou
Lin Qiu
Hongyan Yin
Hui Tan
Hongcheng Shi
Publikationsdatum
11.01.2020
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 4/2020
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-019-02396-3

Weitere Artikel der Ausgabe 4/2020

Abdominal Radiology 4/2020 Zur Ausgabe

Classics in Abdominal Radiology

The hairpin turn

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.